0001209191-22-053659.txt : 20221014 0001209191-22-053659.hdr.sgml : 20221014 20221014160856 ACCESSION NUMBER: 0001209191-22-053659 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20221012 FILED AS OF DATE: 20221014 DATE AS OF CHANGE: 20221014 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Aftab Blake CENTRAL INDEX KEY: 0001886986 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38359 FILM NUMBER: 221311451 MAIL ADDRESS: STREET 1: C/O ADICET BIO, INC. STREET 2: 200 CLARENDON STREET, FLOOR 6 CITY: BOSTON STATE: MA ZIP: 02116 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Adicet Bio, Inc. CENTRAL INDEX KEY: 0001720580 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 813305277 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 200 BERKELEY STREET STREET 2: 19TH FLOOR CITY: BOSTON STATE: MA ZIP: 02116 BUSINESS PHONE: 617-482-2333 MAIL ADDRESS: STREET 1: 200 BERKELEY STREET STREET 2: 19TH FLOOR CITY: BOSTON STATE: MA ZIP: 02116 FORMER COMPANY: FORMER CONFORMED NAME: resTORbio, Inc. DATE OF NAME CHANGE: 20171024 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-10-12 0 0001720580 Adicet Bio, Inc. ACET 0001886986 Aftab Blake C/O ADICET BIO, INC. 200 BERKELEY STREET, 19TH FLOOR BOSTON MA 02116 0 1 0 0 Chief Scientific Officer Common Stock 2022-10-12 4 M 0 3388 7.38 A 52822 D Common Stock 2022-10-12 4 S 0 1646 15.40 D 51176 D Common Stock 2022-10-13 4 F 0 7933 15.92 D 43243 D Stock Option (Right to Buy) 7.38 2022-10-12 4 M 0 3388 0.00 D 2031-10-11 Common Stock 3388 56612 D This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units and does not represent a sale by the Reporting Person. A total of 60,000 shares subject to an employee stock option were granted to the Reporting Person on October 12, 2021. 25% of the shares subject to the stock option vested and became exercisable on October 12, 2022, with the remainder vesting in equal monthly installments for a period of 36 months thereafter, subject to the Reporting Person's continued service with the Issuer. /s/ Nick Harvey, Attorney-in-Fact 2022-10-14